Company Profile
PharmaCyte Biotech Stock Price, News & Analysis
- Ticker:
- PMCB
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.58 USD (-2.52%)
Close
Last updated: July 27, 2026
8.06M USD
Market cap
Why the stock is moving
As of Jul 27, 2026, PMCB closed down 2.52% at $0.5850. No new same-company headline was identified in the current news window.
Company overview
Business overview
PharmaCyte Biotech was a biotechnology company focused on cell encapsulation and oncology before its restructuring and public-market decline. Its story centered on an experimental cancer-delivery platform.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ before restructuring, PharmaCyte sat in specialty biotechnology.
Business Model Characteristics
The business depended on clinical validation, platform feasibility, and the chance to convert a niche concept into value.
Position Within the Biotechnology Landscape
PharmaCyte belongs to the historical or restructuring biotech set rather than the current live public-company universe.
Future catalysts
PharmaCyte is now largely a legacy / closeout story, so the catalysts are any strategic or asset-resolution update rather than a live pipeline event. The market is focused on what value remains.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK
GSK · Source: GSK plc
- 02
Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results
LEGN · Source: Legend Biotech Corporation
- 03
- 04
- 05
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
KYMR · Source: Kymera
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of PharmaCyte Biotech (PMCB)?
PharmaCyte Biotech (PMCB) most recently closed at 0.58 USD, a -2.52% move versus the previous session.
What is the market cap of PharmaCyte Biotech (PMCB)?
PharmaCyte Biotech currently has a market capitalization of 8.06M USD on BioPharmSignal.
What does PharmaCyte Biotech do?
PharmaCyte Biotech was a biotechnology company focused on cell encapsulation and oncology before its restructuring and public-market decline. Its story centered on an experimental cancer-delivery platform.
On which exchange is PMCB stock listed?
PharmaCyte Biotech (PMCB) is associated with NASDAQ, United States, Biopharma.
What is PharmaCyte?
PharmaCyte is now largely a legacy / closeout story, so the catalysts are any strategic or asset-resolution update rather than a live pipeline event.
Which conditions is PharmaCyte Biotech targeting with PharmaCyte?
PharmaCyte Biotech is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does PharmaCyte Biotech describe recent progress with PharmaCyte?
PharmaCyte is now largely a legacy / closeout story, so the catalysts are any strategic or asset-resolution update rather than a live pipeline event.
What is Biotech?
PharmaCyte Biotech was a biotechnology company focused on cell encapsulation and oncology before its restructuring and public-market decline.